- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, is pleased to announce that its co-founder and CEO, Dr. Keith Ward, will be presenting at the Venture Connect meeting, March 20-21 2024, in Raleigh, North Carolina.
Hosted by North Carolina's Council for Entrepreneurial Development, Venture Connect is the premier pitch event for venture investors in the Southeast. The meeting is expected to attract hundreds of seasoned investors and startup company executives over the two-day, in-person event. Kuria is one of 125 companies selected through a rigorous peer-reviewed process to present on-stage during the conference.
Dr. Ward will present updates on Kuria's development programs and further introduce the company to the venture community, and will be available for one-on-one meetings during the event.
About Kuria Therapeutics, Inc.:
Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts
Investor Relations and Media
Kuria Therapeutics:
Corporate Communication